Helix BioPharma Corporation

Aurora, Canada

Helix BioPharma Corporation

Aurora, Canada
SEARCH FILTERS
Time filter
Source Type

Helix will be presenting at 10:50am on Friday, June 2nd, 2017 PR Track A TORONTO, ON--(Marketwired - May 30, 2017) - Helix BioPharma Corp. (TSX: HBP) ( : HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that company Chief Executive Officer and Chief Science Officer, Heman Chao, will be presenting at the upcoming 3rd Annual Immuno-oncology BD&L and Investment Forum ("IOBD&L") taking place on June 2nd, 2017 at the Hyatt Chicago Magnificent Mile Hotel. Taking place on the first day of ASCO, the Sachs Associate Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. Helix will be presenting at 10:50am on Friday, June 2nd PR Track A. "The meeting is a great opportunity for Helix to showcase the company in a forum that includes industry leaders from biotech, pharma and the investment community," said Dr. Heman Chao. Helix will also be attending the upcoming 53rd Annual American Society Clinical Oncology (ASCO) Meeting taking place from June 2nd to June 6th at the McCormick Place, Chicago, Illinois. A copy of the IOBD&L presentation will be available on Helix's website following the meeting. About Helix BioPharma Corp. Helix BioPharma Corp. is an immune-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor ("CAR") based cell therapies. Helix is currently listed on the TSX and FRANKFURT under the symbol "HBP". Cautionary Statements This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to Helix's operations and strategy and its research and development activities are intended to provide information about management's current plans and expectations. Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, risks inherent in Helix's research and development activities and those risks and uncertainties affecting the Company, as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors, estimates or assumptions have been applied in making forward-looking statements, including, without limitation, the safety and efficacy of the Company's drug product candidates; the potential of ongoing research using camelid single domain antibody in making CAR-T for solid tumour, or advancing any of the Company's CAR-T solid tumor candidate toward clinical testing; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support and that the factors described in the Helix Risk Factors will not cause the Company's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.


A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.


Patent
Helix Biopharma Corporation | Date: 2011-05-25

A pharmaceutical composition and method for use in inhibiting growth of cancer cells in a mammalian subject are disclosed. The composition includes a urease enzyme, and associated therewith, a chemical entity effective to enhance the delivery of the enzyme to cancer cells, when the composition is administered to the subject. Also disclosed are a method of enhancing the effectiveness of weakly basic anti-tumor compounds, a method assessing the presence, size or condition a solid tumor in a subject, and a gene therapy composition for treating a cancer in a subject.


Patent
Amorfix Life Sciences and Helix BioPharma Corporation | Date: 2013-06-11

Human prion protein, PrP, selectively presents the epitope MDEYSNQNN (SEQ ID No. 14) when PrP misfolds. The misfolded form of human PrP is associated with various disease states. The present invention provides an antibody useful to detect and treat such diseases, including cancer such as ovarian cancer and lymphomas, and transmissible spongiform encephalopathies such as CJD. Also provided is an immunoconjugate in which the antibody is conjugated with urease as cytotoxin.


Patent
HELIX BIOPHARMA Corporation | Date: 2014-04-03

This disclosure provides antibody-urease conjugates having therapeutic and diagnostic utility. More specifically, the disclosure relates to diagnostic and/or therapeutic conjugates that are prepared by conjugating one or more whole antibodies to ease.


This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.


This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.


This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.


This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.


A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.

Loading Helix BioPharma Corporation collaborators
Loading Helix BioPharma Corporation collaborators